Alkermes plc (ALKS) Stock Quote

Detailed Quote for Alkermes plc (ALKS)

After Hours: $ 17.98

0.00 (0.00%)

Volume: 1.2 k

4:00 PM EST Feb 10, 2012

close 52 Week Information

52 Week High

July 8, 2011

Close: 20.00

52 Week Low

March 3, 2011

Close: 11.86

Today

Last Price
17.98

Change $
0.49

Change %
2.65%

Tick
N/A

Bid
17.53

Bid Size
200

Ask
18.65

Ask Size
200

Open
18.33

High
18.33

Low
17.90

Prev Close
18.47

Last Trade
4:00

Volume
801.26 k

52 Wk Hi
20.00

52 Wk Low
11.86

Market Cap
2.33 b

Ex-Div Date
N/A

Div Rate
N/A

Yield
N/A

Shares
129,736,507

EPS (TTM)
-0.61

PE Ratio
N/A

close Exchange Information Listed On Nasdaq Global Select (NGS) Exchange
NGS

News and Media for Alkermes plc (ALKS)

Sector News | Topic News

News for ALKS

Thu, Feb 09, 2012

4:00 PM

Alkermes' Corporate Presentation to be Webcast at the Leerink Swann 2012 Global Healthcare Conference - Business Wire

Mon, Feb 06, 2012

4:00 PM

Alkermes' Corporate Presentation to be Webcast at the 14th Annual BIO CEO & Investor Conference - Business Wire

Thu, Feb 02, 2012

7:00 AM

Alkermes plc Reports Third Quarter Fiscal 2012 Financial Results - Business Wire

Tue, Jan 31, 2012

7:00 AM

Alkermes Initiates Open-Label Pilot Study of VIVITROL® to Evaluate Impact on Re-Arrest and Re-Incarceration in Offenders with History of Opioid Dependence - Business Wire

Fri, Jan 27, 2012

3:39 PM

FDA Approves BYDUREON(tm) -- The First and Only Once-Weekly Treatment for Type 2 Diabetes - PR Newswire

Thu, Jan 26, 2012

4:00 PM

Alkermes to Host Conference Call to Discuss Financial Results for Third Quarter of Fiscal 2012 - Business Wire

Wed, Jan 04, 2012

7:00 AM

Alkermes Announces Positive Results From Clinical Study of ALKS 5461 for Major Depressive Disorder - Business Wire

Tue, Jan 03, 2012

7:00 AM

Alkermes' Corporate Presentation to be Webcast at the 30th Annual J.P. Morgan Healthcare Conference - Business Wire

Mon, Dec 19, 2011

7:00 AM

Alkermes Initiates Phase 3 Clinical Study of ALKS 9070 for Treatment of Schizophrenia - Business Wire

Mon, Dec 05, 2011

9:01 AM

A Change in Tides - Featured Research on Alkermes Plc and Forest Laboratories, Inc. - Marketwire

Tue, Nov 29, 2011

4:00 PM

Alkermes' Corporate Presentation to be Webcast at the NASDAQ OMX 27th Investor Program - Business Wire

Mon, Sep 12, 2011

7:00 AM

Analyses Find Type 2 Diabetes Patients Treated with BYDUREON(tm) Experienced Reduction in Cardiovascular Risk Factors: Results Presented at EASD 2011 - PR Newswire

Thu, Sep 01, 2011

8:05 AM

Equity Research on Alkermes Inc. and Hospira Inc. - Drug Delivery Sector's Relationship With the FDA - Marketwire

Thu, Aug 25, 2011

9:00 AM

Factors Moving Markets, Worldwide View - Equity Research on Alkermes, Inc. and Forest Laboratories, Inc. - Marketwire

Thu, Jun 30, 2011

8:35 AM

Research on Alkermes Inc. and Hospira Inc. - Drug Delivery Companies Looking for New Revenues - Marketwire

Fri, Sep 17, 2010

12:17 PM

Alkermes shares up 5% on positive FDA panel recommendation for Vivitrol - Accesswire

Fri, Aug 20, 2010

12:35 PM

FDA decision trade with double approval potential - Accesswire

12:35 PM

FDA decision trade with double approval potential - Accesswire

More News for ALKS >>

Tags for Alkermes plc

Research stocks or mutual funds related to Alkermes plc by keywords or tags. Find companies that have a similar focus to ALKS. The keywords below have been associated to ALKS by either user submission or electronic means.

biotechnology company pharmaceutical articles biotech research medical device conference pharmaceutical branding chief executive officer pharmaceutical publication pharmaceutical market analyst reports pharmaceuticals companies generic pharmaceutical niche pharmaceutical colleges in cambridge ma pharmaceutical patents courses in human resources biotechnology market patient software pharmaceutical research and development financial statements annual report pharmaceutical manufacturing company pharma marketing pharmaceutical industry marketing craigslist ma corporate governance human resources system pharmaceutical software pharma manufacturing pharmaceutical package pharma license pharmaceutical supply chain novartis pharmaceuticals kv pharmaceutical company warrick pharmaceutical pharmaceutical executives clinical research cambridge ma lodging pharmaceutical ingredients university cambridge massachusetts pharmaceutical cro active pharmaceutical ingredients massachusetts pharmaceutical promotion r&d manufacturing pharmaceutical sales pharmaceutical conferences clinical trials industry financial career diabetes pharmaceutical distributors